Developing CAR-modified T cells as an effective and safe therapy for childhood brain tumors
Pediatric brain tumors, and their immune microenvironment, present an incredible clinical challenge. Immunotherapy has been explored as a treatment approach, but better specificity and function of antitumor T cells is necessary. The Krenciute laboratory focuses on establishing safe and effective T-cell based therapies for pediatric brain tumors. We also study the brain tumor microenvironment, mechanisms of tumor resistance, and the genetic landscape of tumors and the immune system. Our goal is to enhance the persistence, efficacy, and safety of antigen-specific T cell therapies for clinical applications.
Our lab is focused on engineering pediatric brain tumor-specific T cells and understanding T cell regulation to improve immunotherapeutic approaches for patient populations. By reeducating the immune system, we hope to improve tumor detection along with the persistence, efficacy, and safety of immune effector cells. Chimeric antigen receptor (CAR) T cells enable targeting of specific and unique tumor associated antigens. Our laboratory leverages expertise in CAR T design and production with collaborative partnerships in neuro-oncology, epigenetics, and immunology across, and beyond, St. Jude.
Designing CAR T cells for pediatric brain tumors
Our lab has long been interested in identifying the antigen signatures of pediatric brain tumors to guide the development of CAR T cells. We set out to determine the unique landscape of these tumors and identify differences from the adult disease. Our experiments have defined a hierarchy of tumor specific antigens quite distinct from adults, for which we have engineered and evaluated specific CAR T cells. We use in vitro and in vivo techniques to determine the efficacy of these CAR Ts, creating small iterations in signaling domains to optimize function. We are still exploring possible candidates, and plan to incorporate large scale screening and -omics based approaches to further define the landscape of tumor associated antigens. Much of this work is conducted in close collaboration with the pediatric brain tumor experts Drs. Martine Roussel and Suzy Baker.
Improving T cell functionality, persistence, and safety
We also apply genetic manipulations to optimize CAR T cells, with a particular focus on negative regulators of immune cell function. By knocking out these negative regulators, and investigating the resulting biology, we can improve T cell anti-tumor activity and persistence. In many cases, we know what regulators, genetic or epigenetic, control T cell function, and so we work to explore the mechanisms by which they impact CAR T cell biology and activity.
Understanding the resulting CAR T cell phenotypes, genetic and epigenetic signatures will lead to additional lines of investigation as we work to optimize CAR T cell functionality. Much of this work is conducted in close collaboration with Dr. Ben Youngblood, an expert on T cell epigenetics, and other principal investigators in the Department of Immunology.
Understanding interactions between CAR T cells and brain tumors
In the course of our work, we observed that engineered CAR T cells were not always effective at irradicating a tumor despite robust expression of a particular antigen. As a result, our lab has started exploring the interactions between CAR T cells, tumor cells and the tumor microenvironment. We are interested in determining whether physical properties of the tumor, or immune landscape of the surrounding environment, impact CAR T cell function.
To accomplish robust interrogation of CAR T cell function and efficacy, our lab leverages several technologies and approaches. We have developed in vitro repeat stimulation assays that recapitulate in vivo settings to explore T cell expansion, persistance and killing. We then use multiplex analysis of cytokine secretion to define patterns that might predict persistence. Whole genome, RNA and bisulfide sequencing allow us to explore the genetic and epigenetic landscapes associated with CAR T cell modifications and functional activity. Additionally, we partner with the Center for In Vivo Imaging and Therapeutics to evaluate the preclinical efficacy of CAR T cells in orthotopic mouse models of pediatric brain tumors.
Dr. Giedre Krenciute received her PhD at Baylor College of Medicine where she also completed her postdoc training under the mentorship of Dr. Stephen Gottschalk. After two years as an instructor at St. Jude, Dr. Krenciute was promoted to faculty in 2019. She developed and characterized chimeric antigen receptors specific to brain tumors and has made several key contributions to improve our understanding of CAR T cell function. In 2021, Dr. Krenciute was awarded the Emerging Scientist Award from the Children’s Cancer Research Fund. She also demonstrates remarkable commitment to mentoring, developing the potential of her trainees and junior scientists.
Diverse research team bringing together scientists from four of the seven continents with backgrounds in everything from physics to pharmacy.